Relmada Therapeutics Announces Completion Of Treatment In Company’s Registrational Phase 3 RELIANCE III Trial For Rel-1017 As A Monotherapy For Major Depressive Disorder
Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the completion of patient treatment in RELIANCE III, a monotherapy
Zai Lab To Present Analysis Of The Impact Of Timing For ZEJULA Maintenance Treatment In Newly Diagnosed Advanced Ovarian Cancer At The 2022 International Gynecologic Cancer Society Meeting September 29 – October 1, 2022
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)))), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, will
Applied Molecular Transport Completes Enrollment Of Phase 2 LOMBARD Monotherapy Trial Of Oral AMT-101 In Patients With Moderate-to-Severe Ulcerative Colitis
Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the company has completed enrollment of the Phase 2 LOMBARD trial for AMT-101 in 105 patients with
Veru Announces FDA Has Rescheduled The Meeting Date To Nov. 9 For The Advisory Committee To Review Emergency Use Authorization For Sabizabulin For Hospitalized COVID-19 Patients At High Risk For Acute Respiratory Distress Syndrome; No Change In Agenda
MIAMI, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast
Shockwave Medical Initiates All-Female Coronary Intravascular Lithotripsy Study To Treat Severely Calcified Cardiovascular Disease
EMPOWER CAD is the First Prospective, Female-Only Study of Coronary Interventions
Study Seeks to Confirm Benefits of Shockwave's Coronary IVL in Females Who Historically Have Suffered Less
Inari Medical Announces Results From The Fully Enrolled 800-patient US Cohort Of The FlowTriever FLASH Registry
Inari Medical, Inc. (NASDAQ:NARI) ("Inari") a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive
Sage Therapeutics And Biogen Present New Analyses At Psych Congress Further Evaluating The Efficacy And Safety Of Zuranolone
Sage Therapeutics, Inc. (NASDAQ:SAGE) and Biogen Inc. (NASDAQ:BIIB) today announced new analyses from across the development program for zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical
Heron Therapeutics Announces U.S. FDA Approval Of APONVIE For The Prevention Of Postoperative Nausea And Vomiting
- APONVIE is the first and only intravenous (IV) formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated
for PONV -
- Delivered via a single 30-second IV injection, APONVIE has demonstrated rapid achievement of therapeutic drug levels ideally suited for the surgical setting -